Recent Updates
Recently added Catalysts
MDAI Positive Sentiment Score: 70/100

Spectral AI to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Key Takeaway: Spectral AI, Inc. will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. The company's focus is on leveraging its AI technology, particularly with the DeepView® System, to revolutionize medical diagnostics in wound care. This system is designed to provide quicker and more precise assessment of wound healing, particularly beneficial for patients with burns and diabetic foot ulcers. As a forward-looking statement, the company recognizes the inherent risks and uncertainties that could affect its strategic goals.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent conference showcases company visibility.
  • The innovative DeepView® System aims to improve wound care management significantly.
  • Potential to enhance patient outcomes and reduce healthcare costs.

CONCERNS & RISKS

  • Forward-looking statements involve risks and uncertainties that could impact future performance.
  • Investors are cautioned against relying too heavily on these projections.

Full Press Release Details

DALLAS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
Management will host investor meetings February 13-14, 2024.
Please contact your BTIG representative if you would like to schedule a virtual or in-person meeting with Spectral AI during the conference. For more information about the conference please refer to the BTIG website.
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Frequently Asked Questions

What is Spectral AI focused on?

Spectral AI specializes in medical diagnostics to enhance treatment decisions in wound care.

When will Spectral AI participate in the BTIG Conference?

Spectral AI will participate in the BTIG Conference on February 13-14, 2024.

What is the DeepView® System?

The DeepView® System is a predictive diagnostic device assessing wound healing potential.

How does DeepView® aim to improve patient outcomes?

DeepView® provides faster, more accurate treatment insights, enhancing patient outcomes and lowering costs.

Where is Spectral AI located?

Spectral AI is based in Dallas, Texas.

Last updated: Feb 6, 2024